A cohesive European policy for hepatitis B vaccination, are we there yet?

30Citations
Citations of this article
44Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Despite the availability of safe and effective hepatitis B virus (HBV) vaccines for more than 30 years, the burden of hepatitis B disease is still substantial. In 1992, the WHO recommended the inclusion of HBV vaccination in all national vaccination programmes. As of 2012, 47 of the 53 European countries (89%) had implemented a universal hepatitis B vaccination programme. The most recent countries to follow the recommendation were Ireland (in 2008) and the Netherlands (in 2011). Still, six countries (Denmark, Finland, Iceland, Norway, Sweden and the UK) adopt risk-group-targeted vaccination only, instead of adding a universal vaccination programme. However, changing demography, increasing immigration and the current vaccine costs make the cost-benefit ratios in these remaining low endemicity countries strongly in favour of universal HBV vaccination. Global efforts, including a cohesive European vaccination policy, are essential to control and prevent hepatitis B. © 2014 The Authors Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases.

Cite

CITATION STYLE

APA

Lernout, T., Hendrickx, G., Vorsters, A., Mosina, L., Emiroglu, N., & Van Damme, P. (2014). A cohesive European policy for hepatitis B vaccination, are we there yet? Clinical Microbiology and Infection. Blackwell Publishing Ltd. https://doi.org/10.1111/1469-0691.12535

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free